公开(公告)号：US20240360109A1

公开(公告)日：2024-10-31

申请号：US18293637

申请日：2022-08-03

申请人： SHANGHAI HANSOH BIOMEDICAL CO., LTD. ,  JIANGSU HANSOH PHARMACEUTICAL GROUP CO., LTD.

发明人： Yidong Su ,  Xiaofeng Mao ,  Jun Wang ,  Xiaohan Zhou ,  Wensheng Yu

IPC分类号： C07D405/14 ,  A61K31/454 ,  A61K31/4545 ,  A61K31/496 ,  A61K31/538 ,  A61P3/04 ,  A61P3/10 ,  C07D413/14 ,  C07D471/04

CPC分类号： C07D405/14 ,  A61K31/454 ,  A61K31/4545 ,  A61K31/496 ,  A61K31/538 ,  A61P3/04 ,  A61P3/10 ,  C07D413/14 ,  C07D471/04

摘要： Provided are a polycyclic derivative regulator, a preparation method therefor, and an application thereof. In particular, provided are a compound represented by general formula (I′), a preparation method therefor, a pharmaceutical composition comprising the compound, and an application thereof as a regulator in the preparation of a drug for treating metabolic diseases and related diseases; the substituents in general formula (I′) are the same as those defined in the description.

公开(公告)号：US20240358695A1

公开(公告)日：2024-10-31

申请号：US18643177

申请日：2024-04-23

申请人： Aurobindo Pharma Ltd

发明人： Sreekanth Manikonda ,  Avinash Reddy Manda ,  Siva Kumar Reddy Chamala ,  Nagaprasad Vishnubhotla ,  Sivakumaran Meenakshisunderam

IPC分类号： A61K31/4545 ,  A61K9/20

CPC分类号： A61K31/4545 ,  A61K9/2009 ,  A61K9/2018 ,  A61K9/2027 ,  A61K9/2054 ,  A61K9/2059 ,  A61K9/2095

摘要： The present invention relates to rapidly disintegrating pharmaceutical composition comprising Rimegepant or pharmaceutically acceptable salt thereof, and processes for manufacture thereof.

公开(公告)号：US12121540B2

公开(公告)日：2024-10-22

申请号：US17030335

申请日：2020-09-23

申请人： Nurix Therapeutics, Inc.

发明人： Jennifa Gosling ,  Arthur Sands ,  Sarah Anne Whelan ,  Cristiana Guiducci

IPC分类号： A61K35/17 ,  A61K31/4196 ,  A61K31/454 ,  A61K31/4545 ,  A61K31/506 ,  A61K31/5377 ,  A61K45/06 ,  A61P35/00 ,  A61P37/04 ,  C12N5/0783

CPC分类号： A61K35/17 ,  A61K31/4196 ,  A61K31/454 ,  A61K31/4545 ,  A61K31/506 ,  A61K31/5377 ,  A61K45/06 ,  A61P35/00 ,  A61P37/04 ,  C12N5/0636 ,  C12N2501/2302 ,  C12N2501/2307 ,  C12N2501/2315 ,  C12N2501/2321 ,  C12N2501/72 ,  C12N2506/11

摘要： Methods and compositions using novel Cbl inhibitors for supporting engraftment of immune cells to increase the efficacy of cell-based immunotherapeutics are disclosed. Also provided are cell-based immunotherapy methods and compositions using novel Cbl inhibitors for the propagation of cells desirable for use in cell-based immunotherapies.

公开(公告)号：US12121515B2

公开(公告)日：2024-10-22

申请号：US18366113

申请日：2023-08-07

申请人： NeuroPn Therapeutics, Inc.

发明人： Ish Khanna ,  Sivaram Pillarisetti

IPC分类号： A61K31/4545 ,  A61K31/445 ,  A61K31/454 ,  A61K31/497 ,  A61K31/506 ,  A61K31/5377 ,  A61P25/02 ,  A61P25/16

CPC分类号： A61K31/4545 ,  A61K31/445 ,  A61K31/454 ,  A61K31/497 ,  A61K31/506 ,  A61K31/5377 ,  A61P25/02 ,  A61P25/16

摘要： Described herein are novel piperidine urea derived compounds and their pharmaceutical compositions for the treatment of conditions and diseases mediated by soluble epoxide hydrolase.

公开(公告)号：US20240343722A1

公开(公告)日：2024-10-17

申请号：US18694175

申请日：2022-09-20

申请人： VIFOR (INTERNATIONAL) AG

发明人： Wilm BUHR ,  Aris KALOGERAKIS ,  Klaus-Daniel UMLAND ,  Stefan REIM ,  Vania MANOLOVA ,  Patrick ALTERMATT ,  Anna FLACE

IPC分类号： C07D413/14 ,  A61K31/4439 ,  A61K31/444 ,  A61K31/4545 ,  A61K31/496 ,  A61K31/506 ,  A61K31/5377 ,  A61K45/06 ,  C07D491/056

CPC分类号： C07D413/14 ,  A61K31/4439 ,  A61K31/444 ,  A61K31/4545 ,  A61K31/496 ,  A61K31/506 ,  A61K31/5377 ,  A61K45/06 ,  C07D491/056

摘要： The invention relates to novel compounds of the general formula (1-A) as defined in the application and pharmaceutical compositions comprising them and the use thereof as medicaments, in particular for the use as ferroportin inhibitors, more particularly for the use in the prophylaxis and/or treatment of diseases caused by a lack of hepcidin or iron metabolism disorders leading to increased iron levels or increased iron absorption, and/or iron overload.

公开(公告)号：US20240342159A1

公开(公告)日：2024-10-17

申请号：US18575022

申请日：2022-06-28

申请人： Neurocrine Biosciences, Inc.

发明人： Angel S. Angelov

IPC分类号： A61K31/4745 ,  A61K9/48 ,  A61K31/40 ,  A61K31/407 ,  A61K31/451 ,  A61K31/454 ,  A61K31/4545 ,  A61K31/496 ,  A61K31/519 ,  A61K31/5415 ,  A61K31/551 ,  A61K31/553 ,  A61K31/554

CPC分类号： A61K31/4745 ,  A61K9/4825 ,  A61K9/4858 ,  A61K9/4866 ,  A61K31/40 ,  A61K31/407 ,  A61K31/451 ,  A61K31/454 ,  A61K31/4545 ,  A61K31/496 ,  A61K31/519 ,  A61K31/5415 ,  A61K31/551 ,  A61K31/553 ,  A61K31/554

摘要： Provided herein are methods for the add-on treatment of schizophrenia using a vesicular monoamine transporter isoform 2 (VMAT2) inhibitor. In certain embodiments, the VMAT2 inhibitor is valbenazine or a pharmaceutically acceptable salt thereof.

公开(公告)号：US12116355B2

公开(公告)日：2024-10-15

申请号：US17340201

申请日：2021-06-07

申请人： H. Lundbeck A/S

发明人： Morten Jorgensen ,  Peter Hongaard Andersen ,  Klaus Gjervig Jensen

IPC分类号： C07D295/073 ,  A61K31/451 ,  A61K31/454 ,  A61K31/4545 ,  A61K31/495 ,  A61K31/496 ,  A61K31/519 ,  A61K31/551 ,  A61K31/554 ,  C07B59/00 ,  C07C45/61 ,  C07C45/67 ,  C07D241/04

CPC分类号： C07D295/073 ,  A61K31/451 ,  A61K31/454 ,  A61K31/4545 ,  A61K31/495 ,  A61K31/496 ,  A61K31/519 ,  A61K31/551 ,  A61K31/554 ,  C07B59/002 ,  C07C45/61 ,  C07C45/67 ,  C07D241/04 ,  C07B2200/05

摘要： The present invention relates to deuterated 1-piperazino-3-phenyl-indanes and salts thereof with activity at dopamine receptors D1 and D2 as well as the 5HT2 receptors in the central nervous system, to medicaments comprising such compounds as active ingredients, to the use of such compounds in the treatment of diseases in the central nervous system, and to methods of treatment comprising administration of such compounds.

公开(公告)号：US20240336568A1

公开(公告)日：2024-10-10

申请号：US18742052

申请日：2024-06-13

申请人： Akebia Therapeutics, Inc.

发明人： Thomas P. BLAISDELL ,  Paul E. FLEMING

IPC分类号： C07D213/81 ,  A61K31/4418 ,  A61K31/4436 ,  A61K31/4439 ,  A61K31/444 ,  A61K31/4545 ,  A61K31/4709 ,  A61K31/4725 ,  A61K31/498 ,  A61K31/502 ,  A61K31/5377 ,  C07D213/84 ,  C07D401/04 ,  C07D401/10 ,  C07D401/12 ,  C07D401/14 ,  C07D417/04 ,  C07D471/04 ,  C07D495/04

CPC分类号： C07D213/81 ,  A61K31/4418 ,  A61K31/4436 ,  A61K31/4439 ,  A61K31/444 ,  A61K31/4545 ,  A61K31/4709 ,  A61K31/4725 ,  A61K31/498 ,  A61K31/502 ,  A61K31/5377 ,  C07D213/84 ,  C07D401/04 ,  C07D401/10 ,  C07D401/12 ,  C07D401/14 ,  C07D417/04 ,  C07D471/04 ,  C07D495/04

摘要： The present invention provides, in part, compounds and methods for treating diseases mediated by PHD1 activity (e.g., ischemia reperfusion injury (including but not limited to stroke, myocardial infarction, and acute kidney injury) inflammatory bowel disease, cancer (including colorectal cancer) and liver disease) comprising administering to a subject to a subject a compound of Formula (I), and sub-formulas thereof:




or a pharmaceutically acceptable salt thereof.

公开(公告)号：US20240335431A1

公开(公告)日：2024-10-10

申请号：US18613180

申请日：2024-03-22

申请人： Acerta Pharma B.V.

发明人： Stephen ATKINSON ,  Gerjan DE BRUIN ,  Flavia IZZO ,  Chimed JANSEN ,  Olaf KINZEL ,  Martin PACKER ,  Saskia VERKAIK ,  Robin VOETS

IPC分类号： A61K31/437 ,  A61K31/439 ,  A61K31/4545 ,  A61K31/506 ,  A61K31/5377 ,  A61K31/55 ,  C07D471/04

CPC分类号： A61K31/437 ,  A61K31/439 ,  A61K31/4545 ,  A61K31/506 ,  A61K31/5377 ,  A61K31/55 ,  C07D471/04

摘要： Compounds having the structure of Formula (I):




and pharmaceutically acceptable salts thereof, wherein R1, R2, R3, R4, and A are as defined in the specification; pharmaceutical compositions comprising such compounds and salts; use of such compounds and salts to treat or prevent Menin-mediated conditions; kits comprising such compounds and salts; and methods for manufacturing such compounds and salts.

公开(公告)号：US20240327383A1

公开(公告)日：2024-10-03

申请号：US18578195

申请日：2022-07-14

申请人： YICHANG HUMANWELL PHARMACEUTICAL CO., LTD. ,  TSINGHUA UNIVERSITY

发明人： Jian WANG ,  Xijun SHENG ,  Lie LI ,  Luanyuan TIAN ,  Jinliang LV ,  Miao WANG ,  Hao ZHOU ,  Xiaoqing YANG

IPC分类号： C07D401/14 ,  A61K31/454 ,  A61K31/4545 ,  A61K31/496 ,  A61K31/517 ,  A61K31/5377 ,  A61K31/541 ,  A61P29/00 ,  C07D401/04 ,  C07D405/14 ,  C07D409/14 ,  C07D491/10

CPC分类号： C07D401/14 ,  A61K31/454 ,  A61K31/4545 ,  A61K31/496 ,  A61K31/517 ,  A61K31/5377 ,  A61K31/541 ,  A61P29/00 ,  C07D401/04 ,  C07D405/14 ,  C07D409/14 ,  C07D491/10

摘要： A piperidine derivative, and a pharmaceutical composition thereof, a preparation method therefor, and a use thereof. A compound of the piperidine derivative is as shown in formula (I), and definitions of substituents are detailed in the description. The piperidine derivative can be used as a bifunctional selective ligand for a μ(mu)-opioid peptide receptor (MOPR) and a κ(kappa)-opioid peptide receptor (KOPR), or a bifunctional selective ligand for a MOPR and a nociceptin opioid peptide receptor (NOPR)/opioid receptor like-1 (ORL-1) receptor. Such a compound or a pharmaceutical composition thereof can be used for treating pain, anxiety, depression, alcohol addiction, and substance abuse/dependence.